Investors raised their wallets Thursday for Concert Pharmaceuticals Inc., which priced its initial public offering (IPO) at $14 – the top of its proposed range – after previously upsizing from 5 million to 6 million shares. The stock swelled above the offering price as trading commenced on the Nasdaq Global Market under the ticker “CNCE,” hitting $16.24 before settling back to close at $14.18 for a gain of 18 cents on the day.